Scarica l'app Stockscreener
24.33
3.27%
0.77
Dopo l'orario di chiusura:
24.32
-0.010
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$23.56
Aprire:
$25.24
Volume 24 ore:
17.58M
Relative Volume:
1.59
Capitalizzazione di mercato:
$9.47B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.7869
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-13.54%
1M Prestazione:
-11.66%
6M Prestazione:
-0.41%
1 anno Prestazione:
-53.04%
Intervallo 1D:
$23.66
$25.56
Intervallo di 1 settimana:
$23.48
$27.87
Portata 52W:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.33 | 9.20B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.25 | 105.80B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
646.87 | 67.70B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
440.49 | 57.41B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
851.01 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.68 | 39.86B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say - sharewise.com
Moderna Reports Q3 2025 Financial Results - TipRanks
Moderna : Transcript (MRNA USQ Transcript 2025 11 06 1) - MarketScreener
Moderna Trims Revenue Forecast As Vaccine Demand Slips - Finimize
IR Insights: Recapping Our Third Quarter 2025 Earnings Report - Moderna
Moderna (MRNA) Reports Q3 Revenue and Strategic Developments - GuruFocus
Moderna eyes 2028 breakeven as COVID sales continue to drop - NBC Boston
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic C - GuruFocus
Moderna's losses narrow, Coach-maker's outlook disappoints - Yahoo Finance
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ... - Yahoo Finance
Moderna gains on sharp cost cuts as COVID vaccine declines - The Boston Globe
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast - Benzinga
Moderna leans on cost cuts, pipeline as vaccine sales dip - BioPharma Dive
Moderna Cuts 2025 Forecast After Weak US Vaccine Sales - Finimize
Moderna Q3 2025 Earnings Call Transcript - Benzinga
Moderna eyes 2028 breakeven as Covid sales continue to drop - The Business Journals
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans - TradingView
Investor Outlook: Moderna posts stronger Q3 as cost-cutting cushions weaker COVID vaccine sales - BNN Bloomberg
Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges - Yahoo Finance
Moderna’s Quarter Wasn’t as Bad as It Could Have Been. The Stock Is Up. - Barron's
Moderna’s Quarter Wasn’t As Bad as It Could Have Been. The Stock Is Up. - Barron's
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing - BioSpace
December 26th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Moderna Tightens 2025 Revenue Outlook as Third-Quarter Top-Line Beats Estimates - MarketScreener
Moderna Q3 2025 slides: Cost discipline offsets revenue decline amid market contraction By Investing.com - Investing.com South Africa
Mixed earnings results from Moderna, DoorDash are in focus as stocks trade lower - MarketWatch
Moderna Gains on Sharp Cost Cuts as Covid Vaccine Declines - Yahoo Finance
Earnings call transcript: Moderna’s Q3 2025 earnings beat expectations By Investing.com - Investing.com UK
Moderna: Q3 losses lower than expectedstock jumps pre-market - MarketScreener
Moderna (MRNA) Stock Jumps 5% After Crushing Earnings Expectations - parameter.io
Moderna Surges; Covid Vaccine Sales Decline, But Top Expectations - MSN
Moderna (NASDAQ:MRNA) Posts Better-Than-Expected Sales In Q3, Stock Soars - The Globe and Mail
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline - GuruFocus
Moderna (MRNA) Surpasses Earnings and Revenue Expectations - GuruFocus
Moderna : Presentation (Moderna 3Q25 Earnings Presentation) - MarketScreener
Snap, Lyft, Moderna and Datadog rise premarket; Qualcomm falls By Investing.com - Investing.com Canada
(MRNA) Moderna Expects 2025 Revenue Range $1.6B$2.0B, vs. FactSet Est of $1.89B - MarketScreener
Moderna's Q3 revenue slumps 45% to $1.0 billion - breakingthenews.net
Moderna (MRNA) Projects Lower Cost of Sales for 2025 - GuruFocus
Earnings Flash (MRNA) Moderna Posts Q3 Loss $0.51 a Share, vs. FactSet Est of $2 Loss - MarketScreener
Moderna: Q3 Earnings Snapshot - San Francisco Chronicle
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estima - GuruFocus
Moderna jumps after reporting much smaller Q3 loss than feared; sales also beat estimates - Sherwood News
Moderna Q3 revenue, profit beat estimates on Covid vaccine sales, cost cuts - MarketScreener
Moderna trims top end of full-year forecast on weak COVID vaccine sales - Yahoo! Finance Canada
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - ACCESS Newswire
Moderna trims annual expenses outlook on lower production costs, R&D cuts - MarketScreener
Moderna Swings to a Loss on Fewer Covid-19 Vaccine SalesWSJ - The Wall Street Journal
Moderna Lowers Outlook Following Weak Covid Vaccine Demand - Bloomberg.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.89%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):